# Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

> **NCT04812535** · PHASE2 · TERMINATED · sponsor: **InflaRx GmbH** · enrollment: 30 (actual)

## Conditions studied

- SCC - Squamous Cell Carcinoma of Skin

## Interventions

- **DRUG:** Vilobelimab
- **DRUG:** Vilobelimab + pembrolizumab combination therapy

## Key facts

- **NCT ID:** NCT04812535
- **Lead sponsor:** InflaRx GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-31
- **Primary completion:** 2024-06-04
- **Final completion:** 2024-06-04
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Sponsor decided to stop the development of vilobelimab in cSCC and early terminated the IFX-1-P2.8 trial due to new alternative treatments for cSCC with high efficacy rates.
- **Last updated:** 2025-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04812535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04812535, "Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04812535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*